Dana Cancer Center

Dana-Farber Cancer Institute (DFCI) is a world-renowned cancer research and treatment center based in Boston, Massachusetts, and a principal teaching affiliate of Harvard Medical School. Founded in 1947 by Dr. Sidney Farber, the institute is a founding member of the Dana-Farber/Harvard Cancer Center and is celebrated for its bench-to-bedside model that seamlessly integrates laboratory research with clinical care. Dana-Farber is a major hub for oncology drug development, managing over 1,100 open clinical trials and contributing to the discovery and approval of numerous landmark therapies, including Gleevec and various immune checkpoint inhibitors. The institute operates specialized research centers such as the Belfer Center for Applied Cancer Science and the Center for Cancer Therapeutic Innovation (CCTI), which facilitate extensive collaborations with the biotechnology and pharmaceutical industries.